Global Cancer Monoclonal Antibody Partnering 2010-2015 - Latest Deal Trends, Players, Financials and Forecasts
DUBLIN, Sept. 14, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/tf638f/global_cancer) has announced the addition of the "Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal Trends, Players, Financials and Forecasts" report to their offering.
The Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an understanding and analysis of how and why companies enter cancer monoclonal antibody partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
This report contains over 250 links to online copies of actual cancer monoclonal antibody deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in cancer monoclonal antibody dealmaking
Chapter 3 - Average financial deal terms for cancer monoclonal antibody partnering
Chapter 4 - Leading cancer monoclonal antibody deals
Chapter 5 - Cancer monoclonal antibody contracts directory
Chapter 6 - Future trends and companies in cancer monoclonal antibody deal making
Chapter 7 - Partnering resource centre
For more information visit
http://www.researchandmarkets.com/research/tf638f/global_cancer
Media Contact:
Laura Wood, +353-1-481-1716, press@researchandmarkets.net
Share this article